BioNxt's Preclinical Study Shows 40% Higher Cladribine Delivery

BioNxt Solutions Inc. has released final preclinical results demonstrating that its sublingual oral dissolvable film (ODF) significantly enhances cladribine delivery for treating Multiple Sclerosis (MS). Conducted in a pig model, the study found a 40% increase in systemic drug availability compared to conventional oral tablets.

The sublingual ODF formulation outperformed the oral form by improving systemic drug exposure. With a mean AUC of 39.46 ng·h/mL, compared to 28.11 ng·h/mL for tablets, this finding suggests improved absorption and duration of drug presence in the bloodstream.

BioNxt plans to advance this formulation to human pharmacokinetic studies. The company is optimistic that this needle-free, patient-friendly option could better serve those with MS and potentially, other neuro-immunological conditions.